AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

Ads

You May Also Like

Appointment of Chief Financial Officer

NEW YORK, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), ...

Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information

Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy ...

Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

HOUSTON, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology ...